Blogs

Breast cancer - ASCO18
Abstract 506: PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results. Conclusion: Trastuzumab’s known side effects include a risk for heart problems. The women who had received trastuzumab for less time also had fewer heart problems. Out of those who received 6 months of trastuzumab, 4% had to stop the treatment
oxford_global
Last week London had a pretty good weather, slightly chilly evenings and surprisingly, sun-kissed mornings! Yes, we were there to attend the 5th Biennial Biosimilars & Biobetters Congress in London (since the event was in London. I guess it’s a mandate to start with a weather update J) It was a two-day interactive event addressing various topics including market access strategies, clinical development, opportunities and commercial challenges amongst others. However, I will keep it short
Targetted therapy
Distribution of Anti Pd-1 / Anti PD-L1 by Phase
clinical_dev_biosimilar
As the regulatory frameworks for biosimilar development are evolving in both US and EU, more and more biosimilar developers are entering the competitive landscape. Many commercially successful Oncology biologics are going off-patent in next few years, presenting a lucrative opportunity for biosimilar development. The biosimilars pertaining to these biologics constitute the first wave of mAb biosimilars – Avastin®, Herceptin®, and Rituxan®/MabThera®. These 3 Oncology products have a cumulative global sale of over USD 18 billion
Biosimilar dev in US and EU
As per the 2015 IMS report, the global biologics market is projected to reach 28% of the global pharmaceuticals market by 2020 [1]. This would translate to the biologics market potentially worth USD 390 billion in 2020. As many of the biologics will face patent expiration in the next 5 years, the biosimilar market is forecasted at USD 20 billion by 2020 [1]. Driven by the use of biosimilar products, the potential savings to health
In part 1 of this two part paper, we indicated that even as the western markets are opening up to mAb biosimilars, Indian biosimilar companies have focused on home turfs. In the absence of a crystal ball and presence of several caveats, there is no telling how the market will shape up.  The Indian market has been very receptive to biosimilars and the local biopharmaceutical companies have jumped on the bandwagon. As “present” are the big